Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).
Identifieur interne : 000921 ( Ncbi/Curation ); précédent : 000920; suivant : 000922Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).
Auteurs : Brad A. Racette [États-Unis] ; Mikula Stambuk ; Joel S. PerlmutterSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2002.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Botulinum Toxins, Type A.
- drug effects : Blinking.
- drug therapy : Blepharospasm.
- chemical , therapeutic use : Botulinum Toxins, Type A.
- Female, Humans, Middle Aged, Treatment Outcome.
Abstract
We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.
DOI: 10.1002/mds.10209
PubMed: 12360571
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003930
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003930
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003942
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000921
Links to Exploration step
pubmed:12360571Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).</title>
<author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110</wicri:regionArea>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
<placeName><settlement type="city">Saint-Louis (Missouri)</settlement>
<region type="state">Missouri (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2002">2002</date>
<idno type="RBID">pubmed:12360571</idno>
<idno type="pmid">12360571</idno>
<idno type="doi">10.1002/mds.10209</idno>
<idno type="wicri:Area/PubMed/Corpus">003930</idno>
<idno type="wicri:Area/PubMed/Curation">003930</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003942</idno>
<idno type="wicri:Area/Ncbi/Merge">000921</idno>
<idno type="wicri:Area/Ncbi/Curation">000921</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024).</title>
<author><name sortKey="Racette, Brad A" sort="Racette, Brad A" uniqKey="Racette B" first="Brad A" last="Racette">Brad A. Racette</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110, USA. racetteb@neuro.wustl.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St. Louis, Missouri 63110</wicri:regionArea>
<orgName type="university">École de médecine (Université Washington de Saint-Louis)</orgName>
<placeName><settlement type="city">Saint-Louis (Missouri)</settlement>
<region type="state">Missouri (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stambuk, Mikula" sort="Stambuk, Mikula" uniqKey="Stambuk M" first="Mikula" last="Stambuk">Mikula Stambuk</name>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S" last="Perlmutter">Joel S. Perlmutter</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002" type="published">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Blepharospasm (drug therapy)</term>
<term>Blinking (drug effects)</term>
<term>Botulinum Toxins, Type A (pharmacology)</term>
<term>Botulinum Toxins, Type A (therapeutic use)</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blinking</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blepharospasm</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We report on a patient with cranio-cervical dystonia injected with the new, lower protein formulation of botulinum toxin A who developed secondary resistance to this toxin. Subsequent injections with botulinum toxin B provided substantial reduction of blepharospasm. This is the first reported case of secondary resistance to the new preparation of botulinum toxin A.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000921 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000921 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:12360571 |texte= Secondary nonresponsiveness to new bulk botulinum toxin A (BCB2024). }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:12360571" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |